This site is intended for U.S. healthcare professionals.
Menu
Close
Menu
Close
The information provided below is intended for informational purposes only and is not a comprehensive description of potential coding requirements for NYVEPRIA. Coding and coverage policies change periodically and often without notice. The healthcare provider (HCP) is solely responsible for determining coverage and reimbursement parameters and appropriate coding for treatment of his/her patients. The information provided should not be considered a guarantee of coverage or reimbursement for NYVEPRIA.
In the physician office and hospital outpatient department sites of care, Medicare, Medicaid, and private commercial payers typically recognize the following codes for reporting NYVEPRIA and its administration on claim forms:
The International Classification of Diseases, 10th Revision, Clinical Modification (ICD-10-CM) code set should be used, as appropriate, to report the patient-specific diagnosis.
Reporting the medical necessity for NYVEPRIA may require a primary and secondary diagnosis in some cases. HCPs should verify payer-specific diagnosis coding and sequencing requirements before submitting a claim as they may vary by payer.
With 15+ years of biosimilars experience globally, including more than 1.3 million people treated around the world2,5
To report an adverse event, please call 1-800-438-1985
Pfizer for Professionals 1-800-505-4426
This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.
© 2024 Pfizer Inc. All rights reserved.
Contraindications
NYVEPRIA is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.
Limitations of Use
NYVEPRIA is not indicated for the mobilization of peripheral blood progenitor cells for hematopoietic stem cell transplantation.
Please see full Prescribing Information, Patient Information, and Instructions for Use for NYVEPRIA.